Literature DB >> 15667554

Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity.

Lie Xin Liang1, Qing Zhang, Wei Qian, Xiao Hua Hou.   

Abstract

OBJECTIVE: To establish a model of chronic visceral hypersensitivity in rats and to investigate the effect of tegaserod, a partial 5-hydroxytryptamine-4 receptor agonist, on visceral hypersensitivity.
METHODS: Neonate Sprague-Dawley rats at 8-21 days after birth underwent colorectal distension once daily. Adult rats aged 8-10 postnatal weeks underwent colorectal distension and the abdominal withdrawal reflex (AWR) during the distension was determined. The AWR score was recorded before and after intraperitoneal administration of either tegaserod (treatment group: 0.3 mg/kg) or vehicle (control group).
RESULTS: Changes in the AWR score were dependent on the pressure intensity of the colorectal distension (P < 0.01). At pressures of 40, 60 and 80 mmHg, the AWR scores in the model rats with visceral hypersensitivity were significantly higher than those recorded in the control group (1.95 +/- 0.16 vs 1.35 +/- 0.15, 2.82 +/- 0.12 vs 2.17 +/- 0.13, 3.20 +/- 0.14 vs 2.59 +/- 0.14, P < 0.01). Compared with the controls, tegaserod significantly decreased the AWR scores at the distension pressures of 40, 60 and 80 mmHg (1.95 +/- 0.50 vs 1.32 +/- 0.55, 3.05 +/- 0.48 vs 2.32 +/- 0.54, 3.25 +/- 0.63 vs 2.77 +/- 0.51, P < 0.05).
CONCLUSIONS: Adult rats can develop chronic visceral hypersensitivity after transient colorectal mechanical irritation during their postnatal period. Tegaserod increases the pain threshold to noxious stimuli, suggesting an antinociceptive property in its effect on visceral hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667554     DOI: 10.1111/j.1443-9573.2005.00182.x

Source DB:  PubMed          Journal:  Chin J Dig Dis        ISSN: 1443-9573


  6 in total

1.  The 5HT4 receptor agonist prucalopride suppresses abdominal nociception.

Authors:  O A Lyubashina; I I Busygina; S S Panteleev; A D Nozdrachev
Journal:  Dokl Biol Sci       Date:  2015-05-05

2.  Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM).

Authors:  Jyoti N Sengupta; Aaron Mickle; Pradeep Kannampalli; Russell Spruell; John McRorie; Reza Shaker; Adrian Miranda
Journal:  Neuropharmacology       Date:  2013-12-12       Impact factor: 5.250

Review 3.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 4.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

Review 5.  Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities.

Authors:  Rachel D Moloney; Siobhain M O'Mahony; Timothy G Dinan; John F Cryan
Journal:  Front Psychiatry       Date:  2015-02-16       Impact factor: 4.157

Review 6.  Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity.

Authors:  Chang Myung Oh; Sangkyu Park; Hail Kim
Journal:  Diabetes Metab J       Date:  2016-04       Impact factor: 5.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.